Gut Microbiota: Potential Therapeutic Target for Sickle Cell Disease Pain and Complications.

ABSTRACT:

Aim

Sickle cell disease has witnessed a 41.4% surge from 2000 to 2021, significantly affecting morbidity and mortality rates, particularly in children from regions with elevated under-5 mortality rates. Gut microbiota dysbiosis is increasingly recognised in SCD, exacerbating complications, particularly chronic pain, marked by significant alterations of proinflammatory bacteria abundance. This review explores the therapeutic potential of Akkermansia muciniphila and Roseburia spp. in alleviating SCD-related complications, emphasising their roles in maintaining gut barrier integrity, reducing inflammation, and modulating immune responses.

Method

A literature search up to November 2023 using PubMed, MEDLINE, and Google Scholar databases explored SCD pathophysiology

SUBMITTER: Agbalalah T 

PROVIDER: S-EPMC10965282 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature